Switch to optionsXpress for advanced derivatives trading & earn 50 commission-free trades.
SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator bulldurham, TraderpennyX, Peacefulwendy, TheBestInvest, Pistol Pete, KitchenRat
Search This Board:
Last Post: 3/30/2015 4:20:07 AM - Followers: 521 - Board type: Free - Posts Today: 3

Welcome to PharmaCyte BioTech
FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment


Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious:
Data from Two Clinical Trials in Pancreatic Cancer


ThaiTECT ???????? 14 - Drug Development Part I : International Experiences


Nuvilex/Austrianova declared the winner of the 2014 Best Innovation Award

Encapsulation of Insulin Producing Cells for Diabetes Treatment Using 
Alginate and Cellulose Sulphate as Bioencapsulation Polymers


NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)


PharmaCyte Company Address
   PharmaCyte BioTech, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851

Market Value:
$76,201,902 a/o Mar 11, 2015

Shares Outstanding:
699,292.029 a/o Dec 15, 2014

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

529,206,849 a/o Aug 26, 2014

Short Selling Data

Short Interest: 363,107 (1.685) a/o Feb 13, 2015

For more updated information please visit: 


Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations

Jamien Jones 
Blueprint Life Science Group 
Telephone: 415.375.3340 Ext. 103 



All News Releases: 

All Information about Nuvilex:

What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans.


PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.


Austria Nova Demonstration Video


SMMG Radio Interview with COO Dr. Crabtree ~ 2013

Shareholder Update with CEO & COO via SMMG Interview ~ July 2014

The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool

Management Team:


Kenneth L. Waggoner, Chief Executive Officer and President:

Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.


Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:

Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Walter H. Gunzburg – Chief Scientific Officer:

Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. He was a scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001 and was involved in their IPO. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc., all of which developed/are developing advanced medicinal treatments for cancer. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.

Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years. He was a member of the German Medical Association's Central Commission for Somatic Gene Therapy. He has also interacted with a number of regulatory agencies including the US FDA, EMA, TGA, HSA and Thai-FDA and was on the review panel for the Paul Ehrlich Institute, Langen, Germany. Prof. Gunzburg continues to be an active researcher and has published more than 130 peer-reviewed publications in international scientific and medical journals such as NatureThe Lancet,Proceedings of the National Academy of Sciences USA and Cancer Research as well as co-authoring the first German language textbook on gene therapy. He is also a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine, and continues to be an active reviewer for many top tier journals as well as grant funding agencies.

Dr. Matthias Lohr as Chairman of Scientific Advisory Board:

Matthias Löhr was appointed professor of gastroenterology & hepatology at Karolinska Institutet in 2007, incoming from the Univ. Heidelberg/dkfz. From the times of his MD thesis through PhD and lateron, he concentrated on several aspects of the pancreas, both in clinical medicine, translational and basic sciences. He is heading the Pancreas Research Team at Gastrocentrum and leading the KICancer Diagnose-related network for HPB tumors. For hte European Gastroenterologists (UEG), he is sitting in several committees at the EU in Brussels. He is also leading the Pancreas 2000 program, an educational program for future pancreatologists in Europe.

Stock Chart http://www.otcmarkets.com/stock/NVLX/chart
Company Info http://www.otcmarkets.com/stock/NVLX/company-info
Recent News http://www.otcmarkets.com/stock/NVLX/news
Financials http://www.otcmarkets.com/stock/NVLX/financials
Filings and Disclosure http://www.otcmarkets.com/stock/NVLX/filings
Short Sales http://www.otcmarkets.com/stock/NVLX/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/NVLX/insider-transactions
Research Reports http://www.otcmarkets.com/stock/NVLX/research
Summary http://finance.yahoo.com/q?s=NVLX
Historical Prices http://finance.yahoo.com/q/hp?s=NVLX+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=NVLX
Basic Chart http://finance.yahoo.com/q/bc?s=NVLX+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=NVLX+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=NVLX+Headlines
Press Releases http://finance.yahoo.com/q/p?s=NVLX+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=NVLX+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=NVLX+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=NVLX+Industry
Major Holders http://finance.yahoo.com/q/mh?s=NVLX+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=NVLX+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=NVLX+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=NVLX
Balance Sheet http://finance.yahoo.com/q/bs?s=NVLX
Cash Flow http://finance.yahoo.com/q/cf?s=NVLX+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/NVLX
Market Watch http://www.marketwatch.com/investing/stock/NVLX
Bloomberg http://www.bloomberg.com/quote/NVLX:US
Morningstar http://quotes.morningstar.com/stock/s?t=NVLX
Bussinessweek http://investing.businessweek.com/research/st...icker=NVLX
Barchart http://www.barchart.com/quotes/stocks/NVLX
OTC Short Report http://otcshortreport.com/index.php?index=NVLX
Investopedia http://www.investopedia.com/markets/stocks/NVLX/?wa=0

Features http://www.stockmarketmediagroup.com/features/nvlx/



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NVLX News: Current Report Filing (8-k) 01/09/2015 11:34:14 AM
NVLX News: Nuvilex Announces Name Change to PharmaCyte Biotech 01/07/2015 09:30:00 AM
NVLX News: Nuvilex to Attend 2015 Gastrointestinal Cancers Symposium in San Francisco, January 15-17, 2015 01/06/2015 09:30:00 AM
NVLX News: FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment 12/22/2014 08:30:00 AM
NVLX News: Nuvilex’s Partner Austrianova Successfully Completes First Live-Cell Encapsulation in New Facility 12/18/2014 09:30:00 AM
#33436  Sticky Note PharmaCyte Biotech Inc. >>> Insulin / Type 1 TraderpennyX 03/28/15 03:30:38 PM
#33411  Sticky Note $PMCB Is A Four Bagger Pistol Pete 03/27/15 01:53:26 PM
#32746  Sticky Note Shareholder update... Peacefulwendy 03/16/15 11:28:37 AM
#31958  Sticky Note PharmaCyte Biotech Initiates Expanded Follow-up Study in the bulldurham 02/19/15 09:31:41 AM
#31423  Sticky Note PharmaCyte Biotech Initiates First Preclinical Study of Its TheBestInvest 02/04/15 11:38:18 AM
#18112  Sticky Note EVERYONE please keep your posts on-topic. The topic IH Geek [Dave] 03/14/14 12:28:20 PM
#33474   Blessings World The Promised Land 03/30/15 04:20:06 AM
#33473   $PMCB chart - nice close above the 50 ospreyeye 03/30/15 02:51:01 AM
#33472   BINGO, Exactly! ______________________________________________________________ frosr6 03/30/15 12:58:12 AM
#33471   Yosemite... I would be interested in knowing how efood125 03/29/15 11:40:30 PM
#33470   You nailed it, Bill. This is about yosemite47 03/29/15 10:22:36 PM
#33469   ok...not sure if you got all this from TheSaint09 03/29/15 09:43:41 PM
#33468   Thanks Ducks. You pretty much summed up that avobill 03/29/15 06:34:09 PM
#33467   Yosemite47, That is one of the best posts that avobill 03/29/15 06:31:50 PM
#33466   Yeah, you're right. One of the premier doctors ducks2312 03/29/15 05:36:27 PM
#33465   Here's a question. Do you think that Von Hoff LuCo 03/29/15 04:38:50 PM
#33464   I appreciate your thoughtful words. I can Peacefulwendy 03/29/15 03:30:20 PM
#33463   This historical data is what drew me to Peacefulwendy 03/29/15 02:25:02 PM
#33462   Bill, I wish you and all of your yosemite47 03/29/15 02:23:51 PM
#33461   Straight from that JNCI article... Peacefulwendy 03/29/15 02:19:10 PM
#33460   Well that is exactly what happened to the mddoctor 03/29/15 02:11:07 PM
#33459   Journal Article from national cancer institute http://m.jnci.oxfordjournals.org/ Gmc2020 03/29/15 01:58:39 PM
#33458   I am really interested to hear about the Peacefulwendy 03/29/15 12:18:04 PM
#33457   “The Nuvilex team presents us with a new urup 03/29/15 10:36:22 AM
#33456   “It is my firm belief the Cell-in-a-Box technology urup 03/29/15 10:29:11 AM
#33455   "I am pleased that after many years of urup 03/29/15 10:21:01 AM
#33454   Two additional clinical trials will be conducted in urup 03/29/15 10:12:32 AM
#33453   Progress in the Cancer Program urup 03/29/15 10:11:38 AM
#33452   "In our view, PharmaCyte Biotech sits in an urup 03/29/15 10:09:17 AM
#33451   http://finance.yahoo.com/news/nuvilex-investors-read-between-lines-130000508.htm urup 03/29/15 10:07:03 AM
#33450   Interesting points you made Frosr6.... TheSaint09 03/29/15 09:19:19 AM
#33449   What if PMCB becomes tremendously successful ? DId snowcrab75 03/29/15 08:21:58 AM
#33448   I doubt seriously that your one post restriction avobill 03/29/15 08:14:49 AM
#33447   I believe that there are many on the avobill 03/29/15 08:10:03 AM
#33446   I firmly believe that it is only a avobill 03/29/15 07:54:54 AM
#33445   What if; Big pharma wasn't interested or they frosr6 03/29/15 01:33:18 AM
#33444   Your second concern was because you are here Pistol Pete 03/29/15 12:32:59 AM
#33443   There is always the possibility that big pharma efood125 03/28/15 11:10:52 PM
#33442   First let me say I have no position yosemite47 03/28/15 10:31:21 PM
#33441   Cant assume real positive results. Would love that biojkap 03/28/15 10:25:27 PM
#33440   With this new large exposure and great results hispeed 03/28/15 10:13:21 PM
#33439   rudygerner. you're post is spot on. This will pennyvestor 03/28/15 07:24:13 PM
#33438   Excellent post! Thank you. The Melligen cells encapsulated rudygerner 03/28/15 06:00:26 PM
#33437   Thanks for sticky this excellent post Go $PMCB Pistol Pete 03/28/15 04:35:05 PM
#33436   PharmaCyte Biotech Inc. >>> Insulin / Type 1 TraderpennyX 03/28/15 03:30:38 PM
#33435   Great find my Friend. Go $PMCB http://www.journaltranscript.com/2015/03/pharma Pistol Pete 03/28/15 02:35:29 PM
#33434   Yosemite, what kind of red flags are you biojkap 03/28/15 01:59:29 PM
#33433   I'm on the fence too. I'll wait yosemite47 03/28/15 01:47:45 PM
#33432   Thx! Will continue to work hard! TraderpennyX 03/28/15 09:19:13 AM
#33431   Thanks for all your hard work Penny! Have rball 03/28/15 09:07:30 AM
#33430   Great week and great Board DD. trently 03/28/15 08:16:02 AM
#33429   Pharmacyte Biotech Inc (OTCMKTS:PMCB) Gaines Analysts Attention TraderpennyX 03/28/15 08:05:14 AM
#33428   My pleasure Wendy. And thanks again for all avobill 03/28/15 06:33:43 AM
#33427   Yey http://www.journaltranscript.com/2015/03/pharmacyte-biotech-inc-otcmktspm The Promised Land 03/28/15 05:26:49 AM
#33426   yea...well, there is only so much lipstick available TheSaint09 03/28/15 01:30:51 AM
#33425   Today is March 27 and way past 3pm. ferenc 03/27/15 09:22:49 PM